Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Comment by 37minus4on Sep 07, 2017 2:17pm

236 Views

Post# 26667789

RE:Off label use

It's good that Ryplazim works and doesn't do any harm:

PROMETIC ANNOUNCES POSITIVE LONG TERM CLINICAL DATA ON RYPLAZIM™ IN PLASMINOGEN CONGENITAL DEFICIENCY AND PROVIDES REGULATORY UPDATE

• Ryplazim™ (Plasminogen IV) long-term treatment shown to prevent recurrence of lesions at 48 weeks

• Ryplazim™ (Plasminogen IV) maintains the same safety, tolerability profile without any serious adverse events at 48 weeks

Man, did you erase that push email, too?

33

Bullboard Posts

What will the U.S. election results mean for Canada?